The Beauty Health Company/$SKIN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
Ticker
$SKIN
Sector
Primary listing
Employees
769
Headquarters
Website
SKIN Metrics
BasicAdvanced
$321M
-
-$0.22
1.20
-
Price and volume
Market cap
$321M
Beta
1.2
52-week high
$2.56
52-week low
$0.78
Average daily volume
1.3M
Financial strength
Current ratio
5.15
Quick ratio
3.989
Long term debt to equity
502.096
Total debt to equity
509.075
Interest coverage (TTM)
-3.75%
Profitability
EBITDA (TTM)
-15.715
Gross margin (TTM)
61.50%
Net profit margin (TTM)
-6.13%
Operating margin (TTM)
-14.00%
Effective tax rate (TTM)
-2.47%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
-4.45%
Return on equity (TTM)
-26.54%
Valuation
Price to revenue (TTM)
1.019
Price to book
4.33
Price to tangible book (TTM)
-3.35
Price to free cash flow (TTM)
9.356
Free cash flow yield (TTM)
10.69%
Free cash flow per share (TTM)
0.27
Growth
Revenue change (TTM)
-15.34%
Earnings per share change (TTM)
-75.28%
3-year revenue growth (CAGR)
-1.55%
3-year earnings per share growth (CAGR)
-50.64%
What the Analysts think about SKIN
Analyst ratings (Buy, Hold, Sell) for The Beauty Health Company stock.
Bulls say / Bears say
Consumables net sales grew 8.2% year-over-year to $49.4 million in Q1 2025, making up 71% of total revenue and demonstrating BeautyHealth’s effective shift to a higher-margin, recurring revenue model.
BeautyHealth improved its adjusted gross margin to 71.9% in Q1 2025 from 63.4% a year ago, as better product mix and lower inventory charges supported profitability.
The company ended March 31, 2025, with $373 million in cash and equivalents, ensuring strong liquidity for its strategic investment and growth plans.
Delivery systems net sales fell 43.5% year-over-year to $20.2 million in Q1 2025, highlighting continued difficulties in device placements due to macroeconomic pressures.
Total net sales dropped 14.5% year-over-year to $69.6 million in Q1 2025, showing that rising consumables sales have not fully compensated for weak device revenue.
The refinancing in May 2025 increased the interest rate on $250 million of new convertible secured notes to 7.95% from 1.25%, leading to much higher annual interest expenses.
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2025.
SKIN Financial Performance
Revenues and expenses
SKIN Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for The Beauty Health Company stock?
The Beauty Health Company (SKIN) has a market cap of $321M as of September 15, 2025.
What is the P/E ratio for The Beauty Health Company stock?
The price to earnings (P/E) ratio for The Beauty Health Company (SKIN) stock is 0 as of September 15, 2025.
Does The Beauty Health Company stock pay dividends?
No, The Beauty Health Company (SKIN) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next The Beauty Health Company dividend payment date?
The Beauty Health Company (SKIN) stock does not pay dividends to its shareholders.
What is the beta indicator for The Beauty Health Company?
The Beauty Health Company (SKIN) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.